Latest Insider Transactions at Syneos Health, Inc. (SYNH)
This section provides a real-time view of insider transactions for Syneos Health, Inc. (SYNH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Syneos Health, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Syneos Health, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 03
2020
|
Alistair Macdonald Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,289
-4.0%
|
$668,785
$65.07 P/Share
|
|
Aug 03
2020
|
Alistair Macdonald Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,178
-1.6%
|
$271,570
$65.06 P/Share
|
|
Jul 15
2020
|
Alistair Macdonald Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
37,868
-4.59%
|
$2,272,080
$60.14 P/Share
|
|
Jul 15
2020
|
Alistair Macdonald Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,868
+4.36%
|
$605,888
$16.06 P/Share
|
|
Jul 14
2020
|
Alistair Macdonald Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,173
-0.97%
|
$300,034
$58.9 P/Share
|
|
Jul 14
2020
|
Alistair Macdonald Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,173
+1.91%
|
$51,730
$10.57 P/Share
|
|
Jul 13
2020
|
Alistair Macdonald Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,655
-1.38%
|
$211,990
$58.21 P/Share
|
|
Jul 13
2020
|
Alistair Macdonald Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,655
+1.36%
|
$36,550
$10.57 P/Share
|
|
Jul 06
2020
|
John M. Dineen Director |
BUY
Open market or private purchase
|
Direct |
8,691
+33.28%
|
$512,769
$59.11 P/Share
|
|
Jul 06
2020
|
Michelle Keefe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,500
-2.89%
|
$88,500
$59.11 P/Share
|
|
May 27
2020
|
Matthew E. Monaghan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+15.79%
|
$173,786
$62.43 P/Share
|
|
May 27
2020
|
Bernadette Connaughton Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+37.3%
|
$173,786
$62.43 P/Share
|
|
May 27
2020
|
Kenneth F Meyers Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+15.79%
|
$173,786
$62.43 P/Share
|
|
May 27
2020
|
William E Klitgaard Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+16.45%
|
$173,786
$62.43 P/Share
|
|
May 27
2020
|
John M. Dineen Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+24.29%
|
$173,786
$62.43 P/Share
|
|
May 27
2020
|
Linda S Harty Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+16.45%
|
$173,786
$62.43 P/Share
|
|
May 27
2020
|
Thomas H. Lee Advisors, LLC |
BUY
Grant, award, or other acquisition
|
Direct |
11,212
+20.27%
|
-
|
|
May 20
2020
|
Michelle Keefe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,500
-4.59%
|
$150,000
$60.0 P/Share
|
|
Apr 20
2020
|
Robert Parks EVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,588
-22.37%
|
$175,812
$49.65 P/Share
|
|
Apr 20
2020
|
Robert Parks EVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
377
+2.3%
|
$16,588
$44.48 P/Share
|
|
Mar 20
2020
|
Jason M. Meggs Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,555
+2.64%
|
$127,980
$36.38 P/Share
|
|
Mar 19
2020
|
Paul Colvin Pres., Clinical Solutions |
BUY
Open market or private purchase
|
Direct |
1,300
+4.62%
|
$46,800
$36.65 P/Share
|
|
Mar 05
2020
|
Jason M. Meggs Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,115
+4.14%
|
-
|
|
Mar 05
2020
|
Jason M. Meggs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,094
+6.88%
|
-
|
|
Mar 05
2020
|
Michelle Keefe Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,549
+5.98%
|
$147,686
$14.83 P/Share
|
|
Mar 05
2020
|
Alistair Macdonald Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,217
+4.47%
|
-
|
|
Mar 05
2020
|
Alistair Macdonald Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,258
+11.16%
|
-
|
|
Mar 05
2020
|
Paul Colvin Pres., Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
2,491
+7.82%
|
-
|
|
Mar 05
2020
|
Jonathan Olefson General Counsel & Corp Secty |
BUY
Grant, award, or other acquisition
|
Direct |
1,898
+6.38%
|
-
|
|
Feb 18
2020
|
Alistair Macdonald Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,451
-5.41%
|
$821,766
$66.51 P/Share
|
|
Feb 18
2020
|
Jason M. Meggs Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,680
-4.26%
|
$176,880
$66.51 P/Share
|
|
Feb 18
2020
|
Michelle Keefe Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,887
-4.12%
|
$124,542
$66.51 P/Share
|
|
Jan 27
2020
|
Jason M. Meggs Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
380
-0.6%
|
$23,560
$62.69 P/Share
|
|
Jan 27
2020
|
Alistair Macdonald Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,545
-5.56%
|
$839,790
$62.69 P/Share
|
|
Jan 19
2020
|
Alistair Macdonald Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,293
-0.53%
|
$81,459
$63.83 P/Share
|
|
Jan 19
2020
|
Jason M. Meggs Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
129
-0.2%
|
$8,127
$63.83 P/Share
|
|
Jan 17
2020
|
Robert Parks EVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,135
+20.89%
|
-
|
|
Jan 15
2020
|
Jonathan Olefson General Counsel & Corp Secty |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+20.51%
|
-
|
|
Jan 15
2020
|
Paul Colvin Pres., Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
11,862
+31.7%
|
-
|
|
Jan 15
2020
|
Jason M. Meggs Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,803
+17.86%
|
-
|
|
Jan 15
2020
|
Michelle Keefe Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,862
+20.58%
|
-
|
|
Jan 15
2020
|
Alistair Macdonald Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,770
+16.6%
|
-
|
|
Jan 08
2020
|
Jonathan Olefson General Counsel & Corp Secty |
SELL
Payment of exercise price or tax liability
|
Direct |
1,095
-5.38%
|
$64,605
$59.96 P/Share
|
|
Jan 08
2020
|
Alistair Macdonald Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,155
-4.92%
|
$599,145
$59.96 P/Share
|
|
Jan 08
2020
|
Michelle Keefe Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,559
-4.39%
|
$91,981
$59.96 P/Share
|
|
Jan 08
2020
|
Robert Parks EVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
679
-5.56%
|
$40,061
$59.96 P/Share
|
|
Jan 08
2020
|
Paul Colvin Pres., Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
1,404
-9.3%
|
$82,836
$59.96 P/Share
|
|
Jan 08
2020
|
Jason M. Meggs Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,732
-3.37%
|
$102,188
$59.96 P/Share
|
|
Jan 02
2020
|
Paul Colvin Pres., Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
249
-1.62%
|
$14,691
$59.51 P/Share
|
|
Dec 03
2019
|
Robert Parks EVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
660
-5.13%
|
$35,640
$54.4 P/Share
|